UNSPSC 85921003: Pharmacotherapy for substance abuse treatment, bupropion

This classification denotes the group of activities that yields a substance abuse treatment intervention or procedure of pharmacotherapy for substance abuse treatment, bupropionpharmacotherapy for substance abuse treatment, bupropion. This intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code HZ97ZZZ

UNSPSC 85921003 Pharmacotherapy for substance abuse treatment, bupropion is a Commodity code that names a single pharmaceutical product line, yet state and local procurement activity tagged under this code bears little relevance to bupropion dispensing or abuse-treatment pharmacotherapy. The recent opportunities block instead shows healthcare and social-service procurement across multiple jurisdictions—speech-language pathology staffing (Hillsborough County Public Schools, Florida), substance-abuse cognitive and criminogenic interventions for female offenders (Harris County Community Supervision & Corrections Department, Texas), cellular therapy lab software (UT Health San Antonio), occupational therapy services (Michigan School for the Deaf), physical therapy for jail inmates (Bergen County, New Jersey), and peer support and victim advocacy services across multiple states. These solicitations span RFP, RFQ, and RFSQ notice types, with response dates in October and November 2026. The mismatch between the code's pharmaceutical focus and the actual work being procured—which centers on clinical staffing, behavioral health services, and therapeutic rehabilitation—signals either systematic miscoding or a data-quality issue in the source. State and local procurement offices are not currently buying bupropion or related abuse-treatment pharmacotherapy under this code designation; the code shows no relevant recent activity aligned with its nominal scope.

This code presents minimal opportunity for vendors focused on pharmaceutical procurement or pharmacotherapy supply chains. Interested parties should investigate whether their target jurisdictions have applied the correct UNSPSC classification to their actual buy, as the classification does not match the work being solicited. Business development professionals should treat this as a watch-and-verify signal: confirm with prospective buyers whether they intend substance-abuse pharmacotherapy procurement or whether their recent tagging reflects a classification error that should be corrected in future solicitations.